Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Fig 1.

Schematic diagram showing planned and actual implementation of the intervention (the HighSTEACS pathway).

More »

Fig 1 Expand

Table 1.

Summary of all pre-specified primary and secondary analysis models.

More »

Table 1 Expand

Table 2.

Summary of all post-hoc advanced primary and secondary analysis models.

More »

Table 2 Expand

Table 3.

Summary of adjustment methods with justification.

More »

Table 3 Expand

Fig 2.

A: A forest plot showing pre-specified model results (geometric mean ratios and 95% confidence intervals) from the length of stay efficacy outcome analysis (including modifications to adjust for potential confounders). AFD = Adjusted for demographics, AMC = Adjusted for multiple covariates, APS = Adjusted for propensity score, IPTW = Inverse probability of treatment weighting. B: A forest plot showing advanced post-hoc model results (geometric mean ratios and 95% confidence intervals) from the length of stay efficacy outcome analysis (N = 31,477 for all). AFD = Adjusted for demographics, AMC = Adjusted for multiple covariates, APS = Adjusted for propensity score, IPTW = Inverse probability of treatment weighting.

More »

Fig 2 Expand

Fig 3.

A: A forest plot showing log-odds ratio results and 95% confidence intervals from the pre-specified primary safety outcome analysis (including modifications to adjust for potential confounders). AFD = Adjusted for demographics, AMC = Adjusted for multiple covariates, APS = Adjusted for propensity score, IPTW = Inverse probability of treatment weighting. B: A forest plot showing advanced post-hoc model results (log-odds ratios and 95% confidence intervals) from the primary safety outcome analysis (N = 31,492 for all). AFD = Adjusted for demographics, AMC = Adjusted for multiple covariates, APS = Adjusted for propensity score, IPTW = Inverse probability of treatment weighting.

More »

Fig 3 Expand

Fig 4.

Event rate for the primary safety outcome of myocardial infarction or cardiac death at 30 days by month of presentation from the start of the trial.

More »

Fig 4 Expand